Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis

Background and aims: Non-alcoholic steatohepatitis (NASH) is a chronic disease that can progress to end-stage liver disease (ESLD). A large proportion of early-stage NASH patients remain undiagnosed compared to those with advanced fibrosis, who are more likely to receive disease management intervent...

ver descrição completa

Detalhes bibliográficos
Autores: Schattenberg, Jorn M., Lazarus, Jeffrey V., Newsome, Philip N., Serfaty, Lawrence, Aghemo, Alessio, Augustin, Salvador, Romero Gómez, Manuel, Ratziu, Vlad
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2021
País:España
Recursos:Universidad de Sevilla (US)
Repositório:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/137733
Acesso em linha:https://hdl.handle.net/11441/137733
https://doi.org/10.1111/liv.14825
Access Level:Acceso aberto
Palavra-chave:Burden of disease
Cost-of- illness analysis
Economic impact
Healthcare resource utilisation
Non-alcoholic steatohepatitis (NASH)
id ES_4f491408b7f43bc213823f65a3dffbcf
oai_identifier_str oai:idus.us.es:11441/137733
network_acronym_str ES
network_name_str España
repository_id_str
spelling Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysisSchattenberg, Jorn M.Lazarus, Jeffrey V.Newsome, Philip N.Serfaty, LawrenceAghemo, AlessioAugustin, SalvadorRomero Gómez, ManuelRatziu, VladBurden of diseaseCost-of- illness analysisEconomic impactHealthcare resource utilisationNon-alcoholic steatohepatitis (NASH)Background and aims: Non-alcoholic steatohepatitis (NASH) is a chronic disease that can progress to end-stage liver disease (ESLD). A large proportion of early-stage NASH patients remain undiagnosed compared to those with advanced fibrosis, who are more likely to receive disease management interventions. This study estimated the disease burden and economic impact of diagnosed NASH in the adult population of France, Germany, Italy, Spain and the United Kingdom in 2018. Methods: The socioeconomic burden of diagnosed NASH was estimated using cost-of- illness methodology applying a prevalence approach to estimate the number of adults with NASH and the attributable economic and wellbeing costs. Given undiagnosed patients do not incur costs in the study, the probability of diagnosis is central to cost estimation. The analysis was based on a literature review, databases and consultation with clinical experts, economists and patient groups. Results: The proportion of adult NASH patients with a diagnosis ranged from 11.9% to 12.7% across countries, which increased to 38.8%-39.1% for advanced fibrosis (F3-F4 compensated cirrhosis). Total economic costs were €8548-19 546M. Of these, health system costs were €619-1292M. Total wellbeing costs were €41 536-90 379M. The majority of the undiagnosed population (87.3%-88.2% of total prevalence) was found to have early-stage NASH, which, left untreated, may progress to more resource consuming ESLD over time. Conclusions: This study found that the majority of economic and wellbeing costs of NASH are experienced in late disease stages. Earlier diagnosis and care of NASH patients could reduce future healthcare costs.Wiley-BlackwellMedicina2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/11441/137733https://doi.org/10.1111/liv.14825reponame:idUS. Depósito de Investigación de la Universidad de Sevillainstname:Universidad de Sevilla (US)InglésLiver International, 41 (6), 1227-1242.https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.14825info:eu-repo/semantics/openAccessoai:idus.us.es:11441/1377332026-06-17T12:51:07Z
dc.title.none.fl_str_mv Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis
title Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis
spellingShingle Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis
Schattenberg, Jorn M.
Burden of disease
Cost-of- illness analysis
Economic impact
Healthcare resource utilisation
Non-alcoholic steatohepatitis (NASH)
title_short Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis
title_full Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis
title_fullStr Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis
title_full_unstemmed Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis
title_sort Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis
dc.creator.none.fl_str_mv Schattenberg, Jorn M.
Lazarus, Jeffrey V.
Newsome, Philip N.
Serfaty, Lawrence
Aghemo, Alessio
Augustin, Salvador
Romero Gómez, Manuel
Ratziu, Vlad
author Schattenberg, Jorn M.
author_facet Schattenberg, Jorn M.
Lazarus, Jeffrey V.
Newsome, Philip N.
Serfaty, Lawrence
Aghemo, Alessio
Augustin, Salvador
Romero Gómez, Manuel
Ratziu, Vlad
author_role author
author2 Lazarus, Jeffrey V.
Newsome, Philip N.
Serfaty, Lawrence
Aghemo, Alessio
Augustin, Salvador
Romero Gómez, Manuel
Ratziu, Vlad
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Medicina
dc.subject.none.fl_str_mv Burden of disease
Cost-of- illness analysis
Economic impact
Healthcare resource utilisation
Non-alcoholic steatohepatitis (NASH)
topic Burden of disease
Cost-of- illness analysis
Economic impact
Healthcare resource utilisation
Non-alcoholic steatohepatitis (NASH)
description Background and aims: Non-alcoholic steatohepatitis (NASH) is a chronic disease that can progress to end-stage liver disease (ESLD). A large proportion of early-stage NASH patients remain undiagnosed compared to those with advanced fibrosis, who are more likely to receive disease management interventions. This study estimated the disease burden and economic impact of diagnosed NASH in the adult population of France, Germany, Italy, Spain and the United Kingdom in 2018. Methods: The socioeconomic burden of diagnosed NASH was estimated using cost-of- illness methodology applying a prevalence approach to estimate the number of adults with NASH and the attributable economic and wellbeing costs. Given undiagnosed patients do not incur costs in the study, the probability of diagnosis is central to cost estimation. The analysis was based on a literature review, databases and consultation with clinical experts, economists and patient groups. Results: The proportion of adult NASH patients with a diagnosis ranged from 11.9% to 12.7% across countries, which increased to 38.8%-39.1% for advanced fibrosis (F3-F4 compensated cirrhosis). Total economic costs were €8548-19 546M. Of these, health system costs were €619-1292M. Total wellbeing costs were €41 536-90 379M. The majority of the undiagnosed population (87.3%-88.2% of total prevalence) was found to have early-stage NASH, which, left untreated, may progress to more resource consuming ESLD over time. Conclusions: This study found that the majority of economic and wellbeing costs of NASH are experienced in late disease stages. Earlier diagnosis and care of NASH patients could reduce future healthcare costs.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11441/137733
https://doi.org/10.1111/liv.14825
url https://hdl.handle.net/11441/137733
https://doi.org/10.1111/liv.14825
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Liver International, 41 (6), 1227-1242.
https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.14825
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Wiley-Blackwell
publisher.none.fl_str_mv Wiley-Blackwell
dc.source.none.fl_str_mv reponame:idUS. Depósito de Investigación de la Universidad de Sevilla
instname:Universidad de Sevilla (US)
instname_str Universidad de Sevilla (US)
reponame_str idUS. Depósito de Investigación de la Universidad de Sevilla
collection idUS. Depósito de Investigación de la Universidad de Sevilla
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407810519826432
score 15,301603

Registros relacionados